Evaluation of serum miR-21, miR-29, miR-92, miR-135, miR-210, and miR-1290 biomarkers for diagnosis of colorectal cancer using systematic review and meta-analysis study
- 1Research Center for Molecular Medicine, Institute of Cancer, Hamadan University of Medical Sciences, Hamadan, Iran. , Department of molecular medicine, School of Advanced Medical Sciences and Technologies, Hamadan University of Medical Sciences, Hamadan, Iran
- 2Research Center for Molecular Medicine, Institute of Cancer, Hamadan University of Medical Sciences, Hamadan, Iran.
- 3Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
Abstract
A significant mortality is attributed to a common cancer called colorectal cancer (CRC), and current screening methods for CRC could be improved. Circulating microRNAs (miRNAs) have been identified as promising diagnostic biomarkers in body fluids by their rearrangement between healthy and diseased individuals. This study reviewed studies on miRNAs to investigate their use as screening tools for CRC diagnosis. We searched PubMed, Scopus, and Web of Science (WoS) databases to discover and find relevant miRNAs that could be used as diagnostic biomarkers in CRC. Patient number and demographic characteristics, patient sample type, miRNA detection method, normalization type, and significantly dysregulated miRNAs were recorded. Meta-analysis was performed across studies with similar dysregulated miRNAs. Initially, 1207 identified articles were entered into ENDNOTE, of which 422, 393, and 392 were from Scopus, WoS, and PubMed, respectively. After reviewing and screening studies by two researchers separately and removing duplicates and irrelevant ones, 126 articles remained as final articles. In the meta-analysis, 6 distinct miRNAs including miR-21, miR-29, miR-92, miR-135, miR-210, and miR-1290 were identified in 42 studies. To evaluate the diagnostic accuracy of these miRNAs in colorectal cancer, Forest plots were drawn and statistical analysis was performed using the area under the ROC curve (AUC), sensitivity (95% CI), and specificity (95% CI). The results showed that the identified miRNAs discriminated colorectal cancer (CRC) patients from healthy individuals with high sensitivity and specificity and outperformed conventional tumor biomarkers, making miRNAs a potential blood-based marker for colorectal cancer diagnosis.
Related
- Quantitative dual-energy computed tomography parameters as imaging biomarkers for assessing the histopathologic grade of colorectal cancer
- Toward Precision Colorectal Cancer Screening: Integrating Clinical Risk Stratification, Molecular Biomarkers, and Artificial Intelligence
- Routes to Diagnosis and Stage at Diagnosis of Colorectal Cancer in Patients Aged ≥ 50 Years: A Multicentre Retrospective Cohort Study From North Wales, UK
- Evaluating [¹⁸F]-AlF-FAPI-74 PET/CT for diagnosis of the unfavourable CMS4 colorectal cancer subtype (FoCus study): protocol for a prospective, observational, proof-of-concept clinical study.
- A Cerebral Tumor Embolism from Colorectal Cancer via a Patent Foramen Ovale: A Diagnosis Made by Mechanical Thrombectomy
BibTeX
@article{khezrian2026evaluation,
title = {{Evaluation of serum miR-21, miR-29, miR-92, miR-135, miR-210, and miR-1290 biomarkers for diagnosis of colorectal cancer using systematic review and meta-analysis study}},
author = {Ali Khezrian and Saeid Afshar and Mohammad Mahdi Talimkhani and Amin Doosti-Irani and Ali Mahdavinezhad},
journal = {International Journal of Molecular and Cellular Medicine},
year = {2026},
month = jun,
doi = {10.22088/ijmcm.bums.15.2.1420},
url = {https://doi.org/10.22088/ijmcm.bums.15.2.1420},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Evaluation of serum miR-21, miR-29, miR-92, miR-135, miR-210, and miR-1290 biomarkers for diagnosis of colorectal cancer using systematic review and meta-analysis study
AU - Ali Khezrian
AU - Saeid Afshar
AU - Mohammad Mahdi Talimkhani
AU - Amin Doosti-Irani
AU - Ali Mahdavinezhad
PY - 2026
DA - 2026/06/01
JO - International Journal of Molecular and Cellular Medicine
DO - 10.22088/ijmcm.bums.15.2.1420
UR - https://doi.org/10.22088/ijmcm.bums.15.2.1420
AB - A significant mortality is attributed to a common cancer called colorectal cancer (CRC), and current screening methods for CRC could be improved. Circulating microRNAs (miRNAs) have been identified as promising diagnostic biomarkers in body fluids by their rearrangement between healthy and diseased individuals. This study reviewed studies on miRNAs to investigate their use as screening tools for CRC diagnosis. We searched PubMed, Scopus, and Web of Science (WoS) databases to discover and find relevant miRNAs that could be used as diagnostic biomarkers in CRC. Patient number and demographic characteristics, patient sample type, miRNA detection method, normalization type, and significantly dysregulated miRNAs were recorded. Meta-analysis was performed across studies with similar dysregulated miRNAs. Initially, 1207 identified articles were entered into ENDNOTE, of which 422, 393, and 392 were from Scopus, WoS, and PubMed, respectively. After reviewing and screening studies by two researchers separately and removing duplicates and irrelevant ones, 126 articles remained as final articles. In the meta-analysis, 6 distinct miRNAs including miR-21, miR-29, miR-92, miR-135, miR-210, and miR-1290 were identified in 42 studies. To evaluate the diagnostic accuracy of these miRNAs in colorectal cancer, Forest plots were drawn and statistical analysis was performed using the area under the ROC curve (AUC), sensitivity (95% CI), and specificity (95% CI). The results showed that the identified miRNAs discriminated colorectal cancer (CRC) patients from healthy individuals with high sensitivity and specificity and outperformed conventional tumor biomarkers, making miRNAs a potential blood-based marker for colorectal cancer diagnosis.
SN - 2251-9637
SN - 2251-9645
ER -